Title: Tu1615 Clinical Feasibility and Safety of Modified Neuroleptanalgesia With Midazolam and Pethidine Hydrochloride in Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
Abstract: Endoscopic submucosal dissection (ESD) is widely accepted as a promising endoscopic treatment for gastrointestinal carcinomas, including superficial esophageal squamous cell carcinoma (SEC). However, ESD has major drawbacks, including long treatment time and high prevalence of procedure-related complications. According to the ASGE guidelines for Sedation and anesthesia in GI endoscopy, a little deeper sedation than the appropriate level may be adopted for patients with long-term use of narcotics, alcohol, or neuropsychiatric medications to achieve successful outcomes and avoid the drawbacks of ESD for SEC. In Japan, modified neuroleptanalgesia (m-NLA) is preferred as a sedation and analgesia method in therapeutic endoscopy. The aim of our study was to evaluate the feasibility and safety of m-NLA with midazolam and pethidine hydrochloride (pethidine) in ESD for SEC.
Publication Year: 2012
Publication Date: 2012-04-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot